Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Yoshito Tomimaru

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4432-060X; OpenAlex author ID A5082058900. Sources: OpenAlex.

Their work

Papers
56 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
85
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: 6 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 8 papers · 2024: 11 papers · 2025: 8 papers · 2026: 7 papers

Papers 50 of 56

  1. Relationship Between Radiographic and Pathological Portal Vein-Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparati… Co-author DOI 10.1002/wjs.70395↗
  2. Adjuvant treatment after surgical resection of pancreatic cancer. Co-author DOI 10.1007/s00595-025-03109-8↗
  3. A soft tissue mass around the arteries after pancreatectomy: the association with local recurrence and the impact of neoadjuvant radiotherapy in pancreatic duc… First author DOI 10.1007/s00595-026-03341-w↗
  4. Prognostic significance of neoadjuvant gemcitabine and S-1 chemotherapy with or without concurrent radiation in patients with resectable and borderline resecta… Co-author DOI 10.1016/j.surg.2025.109864↗
  5. Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA. Co-author DOI 10.1038/s41598-026-48779-7↗
  6. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Co-author DOI 10.1371/journal.pone.0345459↗
  7. Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment respo… Co-author DOI 10.3892/ijo.2026.5849↗
  8. Discrepancy Between Radiographic and Pathological Response Assessment in Neoadjuvant Treatment for Pancreatic Cancer: A Comparison Between Neoadjuvant Chemothe… Co-author DOI 10.1002/ags3.70047↗
  9. Prognostic impact of post-neoadjuvant CA19-9 values in pancreatic cancer: more pronounced following neoadjuvant chemotherapy compared to neoadjuvant chemoradio… Co-author DOI 10.1016/j.pan.2025.06.016↗
  10. Response to the letter to the editor: "Refining the prognostic utility of CA19-9 in neoadjuvant therapy for pancreatic cancer: Emphasizing serial monitoring an… Co-author DOI 10.1016/j.pan.2025.09.033↗
  11. Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases. Co-author DOI 10.1016/j.suronc.2025.102225↗
  12. miR-6855-5p Enhances Radioresistance and Promotes Migration of Pancreatic Cancer by Inducing Epithelial-Mesenchymal Transition via Suppressing FOXA1: Potential… Co-author DOI 10.1245/s10434-024-16115-w↗
  13. ASO Author Reflections: Potential of Peripheral Plasma Exosomal miRNA: miR-6855-5p Could Predict Radiosensitivity in Patients with Pancreatic Cancer, and Enhan… Co-author DOI 10.1245/s10434-024-16235-3↗
  14. Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17482-8↗
  15. ASO Author Reflections: Efficacy of SOAT1 Inhibitors against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17667-1↗
  16. Removal of gemcitabine-induced senescent cancer cells by targeting glutaminase1 improves the therapeutic effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.34725↗
  17. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  18. Diagnostic impact of postoperative CA19-9 dynamics on pancreatic cancer recurrence: a single-institution retrospective study. First author DOI 10.1007/s13304-024-01758-x↗
  19. Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plus pancreatic ductal adenocarcinoma patie… Co-author DOI 10.1016/j.ejso.2024.108650↗
  20. Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network anal… Co-author DOI 10.1016/j.pan.2024.09.009↗
  21. Organ-specific variations in tumor marker dynamics in postoperative pancreatic cancer recurrence: Trends in lung and liver recurrence highlighting biological h… Co-author DOI 10.1016/j.suronc.2024.102103↗
  22. ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radi… Co-author DOI 10.1245/s10434-024-15021-5↗
  23. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15118-x↗
  24. ASO Author Reflections: A Novel Mechanism of Anticancer Effect of Skeletal Muscle-Derived Irisin in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15349-y↗
  25. MicroRNA-26a-5p is a reliable biomarker in the adjuvant setting for pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0310328↗
  26. Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality. Co-author DOI 10.3892/ijo.2024.5662↗
  27. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  28. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-023-04531-w↗
  29. Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival. Co-author DOI 10.1007/s00423-023-03089-8↗
  30. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  31. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. Co-author DOI 10.1007/s10147-023-02306-0↗
  32. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma U… First author DOI 10.1245/s10434-022-12985-0↗
  33. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancre… First author DOI 10.1245/s10434-022-13024-8↗
  34. The impact of cellular senescence and senescence‑associated secretory phenotype in cancer‑associated fibroblasts on the malignancy of pancreatic cancer. Co-author DOI 10.3892/or.2023.8535↗
  35. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Co-author DOI 10.1016/j.isci.2022.104659↗
  36. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11668-0↗
  37. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11745-4↗
  38. Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvan… Co-author DOI 10.1002/ags3.12418↗
  39. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.04.029↗
  40. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function. Co-author DOI 10.1007/s00280-019-04005-y↗
  41. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07927-2↗
  42. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep42339↗
  43. A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients. Co-author DOI 10.3892/ijo.2015.3258↗
  44. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Co-author DOI 10.3892/ol.2015.4057↗
  45. Implications of peritoneal lavage cytology in resectable left-sided pancreatic cancer. Co-author DOI 10.1007/s00595-014-0964-7↗
  46. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Co-author DOI 10.1093/jjco/hyu224↗
  47. Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000205↗
  48. The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. Co-author DOI 10.3892/mco.2015.490↗
  49. Cyclin G2: A novel independent prognostic marker in pancreatic cancer. Co-author DOI 10.3892/ol.2015.3667↗
  50. [Three Resected Cases of Metachronous Pancreatic Cancer Successfully Treated with Repeated Pancreatectomy]. First author PMID 26805359↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 53 shared papers, 2013–2026 · strength 7.86
  2. Daisaku Yamada · 37 shared papers, 2015–2026 · strength 6.91
  3. Hidetoshi Eguchi · 48 shared papers, 2013–2026 · strength 6.47
  4. Yoshifumi Iwagami · 34 shared papers, 2013–2026 · strength 5.71
  5. Tadafumi Asaoka · 30 shared papers, 2014–2026 · strength 4.82
  6. Kazuki Sasaki · 25 shared papers, 2022–2026 · strength 4.63
  7. Hirofumi Akita · 24 shared papers, 2013–2026 · strength 4.17
  8. Hidenori Takahashi · 21 shared papers, 2021–2026 · strength 3.79
  9. Shinichiro Hasegawa · 14 shared papers, 2014–2026 · strength 2.21
  10. Hidetoshi Eguchi · 7 shared papers, 2025–2026 · strength 2.05
  11. Masahiro Tanemura · 14 shared papers, 2013–2026 · strength 1.83
  12. Kunihito Gotoh · 11 shared papers, 2017–2024 · strength 1.41
  13. Satoru Miyahara · 6 shared papers, 2024–2026 · strength 1.37
  14. Hiroki Ueda · 5 shared papers, 2023–2025 · strength 0.96
  15. Masahiko Kubo · 5 shared papers, 2020–2025 · strength 0.89
  16. Naoko Sekiguchi · 3 shared papers, 2025–2026 · strength 0.72
  17. Hiroaki Nagano · 15 shared papers, 2013–2020 · strength 0.67
  18. Keisuke Toya · 3 shared papers, 2023–2026 · strength 0.59
  19. Yutaka Takeda · 4 shared papers, 2017–2026 · strength 0.57
  20. Yu Takeda · 3 shared papers, 2022–2024 · strength 0.50
  21. Hideshi Ishii · 7 shared papers, 2014–2024 · strength 0.48
  22. Yosuke Mukai · 2 shared papers, 2024–2026 · strength 0.46
  23. Ryosuke Maki · 2 shared papers, 2025 · strength 0.44
  24. Hiroshi Wada · 2 shared papers, 2024–2026 · strength 0.39
  25. Tomoki Sugimoto · 2 shared papers, 2024 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.